With ubituximab, a high percentage of patients maintained no signs of disease activity.

Published Date: 01 Mar 2023

After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.

Read Full News

Latest News

Ionis Pharma Prices First FDA-approved Treatment for Alexander Disease At $285,000 Per Dose

Ionis Pharmaceuticals said on Friday it would price its newly approved therapy ⁠to treat Alexander disease at $285,000 per dose, a day after the U.S. FDA cleared the...

New Migraine Prevention Guidelines Released

Updated migraine prevention guidelines recommend preventive treatment for patients with ≥ 4 migraine days per month and incorporate CGRP-targeted therapies into individualized treatment selection.

Novartis Pauses Trials Of Experimental Cell Therapy After Three Deaths

Novartis said on Tuesday it paused eight clinical trials of an experimental cell therapy, called rap-cel, targeting autoimmune and neurological disorders in late ⁠August,...

Cerebral Palsy Linked to Gaps in Gynecologic Care

Cerebral palsy in women is associated with markedly reduced odds of receiving routine preventive gynecologic care.

Borderline Personality: Evidence Has Evolved. Care Hasn’t

A quiet revolution in borderline personality disorder has exposed a disconnect: Treatment works, recovery is possible, yet outdated assumptions continue to shape clinical care.

New Stroke Rehab Guideline Calls for Earlier, Broader Care

The first update to adult stroke rehabilitation and recovery guidelines in a decade emphasizes early, individualized care addressing physical, cognitive, communication, and mental health needs.

Todays Updates

FDA Approves Camizestrant for ESR1-Mutated Breast Cancer

The accelerated approval enables an endocrine therapy switch when the ESR1 resistance mutation is detected, rather than waiting for evidence of disease progression.

Todays Updates

FDA Approves Camizestrant for ESR1-Mutated Breast Cancer

The accelerated approval enables an endocrine therapy switch when the ESR1 resistance mutation is detected, rather than waiting for evidence of disease progression.

Latest News

Ionis Pharmaceuticals said on Friday it would price its newly approved therapy ⁠to treat Alexander disease at $285,000 per dose, a day after the U.S. FDA cleared the...

Updated migraine prevention guidelines recommend preventive treatment for patients with ≥ 4 migraine days per month and incorporate CGRP-targeted therapies into individualized treatment selection.

Novartis said on Tuesday it paused eight clinical trials of an experimental cell therapy, called rap-cel, targeting autoimmune and neurological disorders in late ⁠August,...

Cerebral palsy in women is associated with markedly reduced odds of receiving routine preventive gynecologic care.

A quiet revolution in borderline personality disorder has exposed a disconnect: Treatment works, recovery is possible, yet outdated assumptions continue to shape clinical care.

The first update to adult stroke rehabilitation and recovery guidelines in a decade emphasizes early, individualized care addressing physical, cognitive, communication, and mental health needs.

News All Time

Leptomeningeal Metastases: Early Recognition, Diagnosis, and Multidisciplinary Care

Leptomeningeal Metastases: Early Recognition, Diagnosis, and Multidisciplinary Care

Decoding Leptomeningeal Metastases: Strategies for Early Detection and Accurate Diagnosis

Decoding Leptomeningeal Metastases: Strategies for Early Detection and Accurate Diagnosis

Superagers' Exceptional Memory Can't Be Explained by Genes Alone, Study Finds

Inherited Alzheimer's risk didn't differ between superagers and cognitively average older adults

Diarrhea Bug Outbreak Hits 4 More States; Fauci to Testify; Doc Dies in House Fire

Health news and commentary gathered by MedPage Today staff

Hold Off on JAK Inhibitors in Rheumatoid Arthritis Until After Shingles Vax?

Good things come to those who wait -- and to those who don't wait

FDA Approves Tylenol With Naproxen Combination

First OTC fixed-dose combination product to pair acetaminophen with naproxen sodium

FDA Panel Finds a Peptide It Doesn't Like

Over 2-day meeting, six of seven peptides are recommended for adding to bulk compounding list

Brain Worm Culprit in Woman's Hallucinations, Incoherent Speech

MRI uncovers neurocysticercosis in a 52-year-old woman

First-in-Class Drug for ADHD Wins FDA Approval

Triple reuptake inhibitor centanafadine is indicated for patients ages 6 years and older

FDA Scientists Raise Questions About Duchenne Drug

Agency says deramiocel did not meet phase III trial endpoints, contrary to reported data

Feds Delay Autism Meeting; Wildfire Smoke and Migraine; Mortality and MS

News and commentary from the world of neurology and neuroscience

Sugar Rationing in Early Life Linked to Lower Dementia Risk Decades Later

Long-term study looks at what happened when sugar was scarce

FDA Committee Votes Down Duchenne Drug

Agency staff and drug developer disagree on endpoints

Alzheimer's Paper Retracted; MS Before Epstein-Barr Infection; Brain Aging Map

News and commentary from the world of neurology and neuroscience

Fauci Successor Imminent; CDC Expands Outbreak List; Pesticides Linked to ALS

Health news and commentary gathered by MedPage Today staff

FDA Approves First-in-Class Narcolepsy Drug

Oveporexton treats more than symptoms, restores orexin signaling

Recommended News For You

Mutation Clearance After Transplant Linked to Better Outcomes in Myelofibrosis

Progress in Early Cancer Diagnosis; Breast Cancer in Younger Women; Diet and Cancer.

In CML Patients With New Diagnoses, STAMP Inhibitor Outperforms Imatinib and Second-Gen TKIs.

Colorectal Cancer Screening Uptake Tripled in 45-49 Age Group

How Do Younger People Fare With Stool Tests for CRC Screening?

Cancer Warnings on Alcohol? Surge in GI Illnesses; Swab Detects Kids' Asthma Type

In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.

Recommended Articles For You

Obesity as a major risk factor for cancer 

Liquid Biopsy: A Game-Changer in T-Cell Lymphoma Detection and Management 

Understanding Carcinoid Tumors: Diagnosis, Symptoms, and Treatment Options  

Clinical Pharmacology of Hypoxia-Activated Anticancer Prodrugs 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

What Could This Exploratory 5-Year Survival Data in Adjuvant NSCLC Treatment Mean?

2.

Genetics and Genetic Testing to Inform Myelofibrosis Clinical Management.

3.

Through the activation of bitter taste receptors, lidocaine has the potential to kill some cancer cells.

4.

Algorithm that predicts pancreatic cancer metastasis could help avoid unnecessary surgeries

5.

The Effect of Common Steroids on Cancer Treatments.

1.

Cardiotoxicity Beyond Anthracyclines: Redefining Risk in the Cardio-Oncology Era

2.

Precision Oncology: How Personalized Medicine is Transforming Cancer Treatment

3.

Unlocking the Mysteries of Lymphoblastic Lymphoma: A Journey Into the Unknown

4.

Virtual Survivorship Platforms in Cancer Care: Transforming Post-Treatment Support and Outcomes

5.

Radiation in Oncology: Advances, Applications, and Accessibility

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients

2.

CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion

3.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II

4.

From Relapse to Remission : Chasing the Invisible and Redefining Long-Term Survival in Adult R/R B-Cell ALL

5.

Exploring the Hospitalization Burden in Refractory and Relapsed ALL

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot